

Global Targeted Protein Degradation (TPD) Therapy Drugs Market Growth 2026-2032

<https://marketpublishers.com/r/G22EDE2BB372EN.html>

Date: January 2026

Pages: 177

Price: US\$ 3,660.00 (Single User License)

ID: G22EDE2BB372EN

Abstracts

The global Targeted Protein Degradation (TPD) Therapy Drugs market size is predicted to grow from US\$ 19801 million in 2025 to US\$ 39443 million in 2032; it is expected to grow at a CAGR of 10.9% from 2026 to 2032.

In 2025, global Targeted protein degradation (TPD) Therapy Drugs reached approximately 1338 K Units, with an average global market price of around 121.33 USD per Unit.

Targeted Protein Degradation (TPD) therapy drugs are a class of innovative medicines that treat disease by selectively eliminating specific proteins inside cells, rather than merely inhibiting their activity. These therapies work by harnessing the cell's natural protein disposal systems, most commonly the ubiquitin–proteasome pathway or, in some cases, lysosomal degradation pathways, to remove disease-causing or disease-driving proteins.

Targeted protein degradation (TPD) Therapy Drugs are an emerging class of small-molecule medicines designed to treat disease by selectively removing, rather than merely inhibiting, specific proteins through the cell's own ubiquitin–proteasome degradation system. This “event-driven” mechanism addresses several persistent pain points in drug development: it can overcome situations where conventional inhibitors lose effectiveness due to resistance mutations, it can achieve deeper and more sustained pathway control by eliminating the target protein altogether, and it opens new possibilities for proteins that are difficult to modulate with classic active-site binding strategies. Industry momentum is being fueled by rapid advances in target biology and structural design, growing confidence in the translational value of targeted protein degradation, and strong demand in areas such as oncology and immune-mediated

diseases where durable responses and differentiation matter most. Looking ahead, market potential is supported by an expanding pipeline of degrader programs, improving chemistry and drug-like properties that enable more practical dosing and broader tissue reach, and the likelihood that successful Targeted protein degradation (TPD) Therapy Drugs will complement—rather than simply replace—existing targeted therapies, creating a meaningful new layer of precision medicine built around controlling protein levels instead of just protein activity.

The upstream raw materials for Targeted Protein Degradation (TPD) Therapy Drugs mainly include target protein (POI) ligands, E3 ligase ligands, excipients, etc. Typical suppliers include Bio-Techne, Merck, Sigma-Aldrich, Enamine, etc. The downstream applications are mainly in the treatment of cancer, immune diseases, etc.

The production capacity of Targeted protein degradation (TPD) Therapy Drugs varies significantly depending on the technology route, production stage, and commercialization progress. The gross profit margin of Targeted protein degradation (TPD) Therapy Drugs is usually between 70-80%.

United States market for Targeted Protein Degradation (TPD) Therapy Drugs is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Targeted Protein Degradation (TPD) Therapy Drugs is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Targeted Protein Degradation (TPD) Therapy Drugs is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Targeted Protein Degradation (TPD) Therapy Drugs players cover BMS, Arvinas, Kymera, Nurix, C4 Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the “Targeted Protein Degradation (TPD) Therapy Drugs Industry Forecast” looks at past sales and reviews total world Targeted Protein Degradation (TPD) Therapy Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted Protein Degradation (TPD) Therapy Drugs sales for 2026 through 2032. With Targeted Protein

Degradation (TPD) Therapy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Targeted Protein Degradation (TPD) Therapy Drugs industry.

This Insight Report provides a comprehensive analysis of the global Targeted Protein Degradation (TPD) Therapy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Protein Degradation (TPD) Therapy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Targeted Protein Degradation (TPD) Therapy Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Protein Degradation (TPD) Therapy Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Protein Degradation (TPD) Therapy Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Protein Degradation (TPD) Therapy Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

PROTAC

Molecular Glues

Others

Segmentation by Target Protein:

Degradation of Transcription Factors Type

Degradation of Scaffold Proteins Type

Others

Segmentation by Administration Route:

Oral Drugs

Injectable Drugs

Others

Segmentation by Application:

Cancer

Immune Diseases

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

BMS

Arvinas

Kymera

Nurix

C4 Therapeutics

Cullgen

Kintor Pharma

Prelude Therapeutics

AbbVie

Accutar

AnHorn Medicines

Astellas

Auron Therapeutics

Axter Therapeutics

Biotheryx

Dialectic Therapeutics

Hinova

Hinova Pharmaceuticals

Haisco

Leadingtac

Mitsubishi Tanabe Pharma America

NiKang Therapeutics

Ubix Therapeutics

Foghorn Therapeutics

Beigene, Ltd.

Jiangsu Hengrui Medicine

Qilu Pharmaceutical

Simcere Pharma

Chia Tai Tianqing Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Targeted Protein Degradation (TPD) Therapy Drugs market?

What factors are driving Targeted Protein Degradation (TPD) Therapy Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Targeted Protein Degradation (TPD) Therapy Drugs market opportunities vary by end market size?

How does Targeted Protein Degradation (TPD) Therapy Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Annual Sales 2021-2032

2.1.2 World Current & Future Analysis for Targeted Protein Degradation (TPD) Therapy Drugs by Geographic Region, 2021, 2025 & 2032

2.1.3 World Current & Future Analysis for Targeted Protein Degradation (TPD) Therapy Drugs by Country/Region, 2021, 2025 & 2032

2.2 Targeted Protein Degradation (TPD) Therapy Drugs Segment by Type

2.2.1 PROTAC

2.2.2 Molecular Glues

2.2.3 Others

2.2.4 Targeted Protein Degradation (TPD) Therapy Drugs Sales by Type

2.2.4.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Type (2021-2026)

2.2.4.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue and Market Share by Type (2021-2026)

2.2.4.3 Global Targeted Protein Degradation (TPD) Therapy Drugs Sale Price by Type (2021-2026)

2.3 Targeted Protein Degradation (TPD) Therapy Drugs Segment by Target Protein

2.3.1 Degradation of Transcription Factors Type

2.3.2 Degradation of Scaffold Proteins Type

2.3.3 Others

2.3.4 Targeted Protein Degradation (TPD) Therapy Drugs Sales by Target Protein

2.3.4.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market

Share by Target Protein (2021-2026)

2.3.4.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue and Market Share by Target Protein (2021-2026)

2.3.4.3 Global Targeted Protein Degradation (TPD) Therapy Drugs Sale Price by Target Protein (2021-2026)

2.4 Targeted Protein Degradation (TPD) Therapy Drugs Segment by Administration Route

2.4.1 Oral Drugs

2.4.2 Injectable Drugs

2.4.3 Others

2.4.4 Targeted Protein Degradation (TPD) Therapy Drugs Sales by Administration Route

2.4.4.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Administration Route (2021-2026)

2.4.4.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue and Market Share by Administration Route (2021-2026)

2.4.4.3 Global Targeted Protein Degradation (TPD) Therapy Drugs Sale Price by Administration Route (2021-2026)

2.5 Targeted Protein Degradation (TPD) Therapy Drugs Segment by Application

2.5.1 Cancer

2.5.2 Immune Diseases

2.5.3 Others

2.5.4 Targeted Protein Degradation (TPD) Therapy Drugs Sales by Application

2.5.4.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Sale Market Share by Application (2021-2026)

2.5.4.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue and Market Share by Application (2021-2026)

2.5.4.3 Global Targeted Protein Degradation (TPD) Therapy Drugs Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Breakdown Data by Company

3.1.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Annual Sales by Company (2021-2026)

3.1.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Company (2021-2026)

3.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Annual Revenue by

Company (2021-2026)

3.2.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Company (2021-2026)

3.2.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Company (2021-2026)

3.3 Global Targeted Protein Degradation (TPD) Therapy Drugs Sale Price by Company

3.4 Key Manufacturers Targeted Protein Degradation (TPD) Therapy Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Targeted Protein Degradation (TPD) Therapy Drugs Product Location Distribution

3.4.2 Players Targeted Protein Degradation (TPD) Therapy Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR TARGETED PROTEIN DEGRADATION (TPD) THERAPY DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Targeted Protein Degradation (TPD) Therapy Drugs Market Size by Geographic Region (2021-2026)

4.1.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Targeted Protein Degradation (TPD) Therapy Drugs Market Size by Country/Region (2021-2026)

4.2.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Annual Sales by Country/Region (2021-2026)

4.2.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Annual Revenue by Country/Region (2021-2026)

4.3 Americas Targeted Protein Degradation (TPD) Therapy Drugs Sales Growth

4.4 APAC Targeted Protein Degradation (TPD) Therapy Drugs Sales Growth

4.5 Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Growth

4.6 Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Growth

5 AMERICAS

5.1 Americas Targeted Protein Degradation (TPD) Therapy Drugs Sales by Country

5.1.1 Americas Targeted Protein Degradation (TPD) Therapy Drugs Sales by Country (2021-2026)

5.1.2 Americas Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Country (2021-2026)

5.2 Americas Targeted Protein Degradation (TPD) Therapy Drugs Sales by Type (2021-2026)

5.3 Americas Targeted Protein Degradation (TPD) Therapy Drugs Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Targeted Protein Degradation (TPD) Therapy Drugs Sales by Region

6.1.1 APAC Targeted Protein Degradation (TPD) Therapy Drugs Sales by Region (2021-2026)

6.1.2 APAC Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Region (2021-2026)

6.2 APAC Targeted Protein Degradation (TPD) Therapy Drugs Sales by Type (2021-2026)

6.3 APAC Targeted Protein Degradation (TPD) Therapy Drugs Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Targeted Protein Degradation (TPD) Therapy Drugs by Country

7.1.1 Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales by Country (2021-2026)

7.1.2 Europe Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Country (2021-2026)

7.2 Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales by Type (2021-2026)

7.3 Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs by Country

8.1.1 Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales by Country (2021-2026)

8.1.2 Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Country (2021-2026)

8.2 Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales by Type (2021-2026)

8.3 Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Targeted Protein Degradation (TPD) Therapy Drugs

10.3 Manufacturing Process Analysis of Targeted Protein Degradation (TPD) Therapy Drugs

10.4 Industry Chain Structure of Targeted Protein Degradation (TPD) Therapy Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Targeted Protein Degradation (TPD) Therapy Drugs Distributors

11.3 Targeted Protein Degradation (TPD) Therapy Drugs Customer

12 WORLD FORECAST REVIEW FOR TARGETED PROTEIN DEGRADATION (TPD) THERAPY DRUGS BY GEOGRAPHIC REGION

12.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Market Size Forecast by Region

12.1.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Forecast by Region (2027-2032)

12.1.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Targeted Protein Degradation (TPD) Therapy Drugs Forecast by Type (2027-2032)

12.7 Global Targeted Protein Degradation (TPD) Therapy Drugs Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 BMS

13.1.1 BMS Company Information

13.1.2 BMS Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.1.3 BMS Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue,

Price and Gross Margin (2021-2026)

13.1.4 BMS Main Business Overview

13.1.5 BMS Latest Developments

13.2 Arvinas

13.2.1 Arvinas Company Information

13.2.2 Arvinas Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.2.3 Arvinas Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Arvinas Main Business Overview

13.2.5 Arvinas Latest Developments

13.3 Kymera

13.3.1 Kymera Company Information

13.3.2 Kymera Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.3.3 Kymera Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Kymera Main Business Overview

13.3.5 Kymera Latest Developments

13.4 Nurix

13.4.1 Nurix Company Information

13.4.2 Nurix Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.4.3 Nurix Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Nurix Main Business Overview

13.4.5 Nurix Latest Developments

13.5 C4 Therapeutics

13.5.1 C4 Therapeutics Company Information

13.5.2 C4 Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.5.3 C4 Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 C4 Therapeutics Main Business Overview

13.5.5 C4 Therapeutics Latest Developments

13.6 Cullgen

13.6.1 Cullgen Company Information

13.6.2 Cullgen Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.6.3 Cullgen Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Cullgen Main Business Overview

13.6.5 Cullgen Latest Developments

13.7 Kintor Pharma

13.7.1 Kintor Pharma Company Information

13.7.2 Kintor Pharma Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.7.3 Kintor Pharma Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Kintor Pharma Main Business Overview

13.7.5 Kintor Pharma Latest Developments

13.8 Prelude Therapeutics

13.8.1 Prelude Therapeutics Company Information

13.8.2 Prelude Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.8.3 Prelude Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Prelude Therapeutics Main Business Overview

13.8.5 Prelude Therapeutics Latest Developments

13.9 AbbVie

13.9.1 AbbVie Company Information

13.9.2 AbbVie Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.9.3 AbbVie Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 AbbVie Main Business Overview

13.9.5 AbbVie Latest Developments

13.10 Accutar

13.10.1 Accutar Company Information

13.10.2 Accutar Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.10.3 Accutar Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Accutar Main Business Overview

13.10.5 Accutar Latest Developments

13.11 AnHorn Medicines

13.11.1 AnHorn Medicines Company Information

13.11.2 AnHorn Medicines Targeted Protein Degradation (TPD) Therapy Drugs

Product Portfolios and Specifications

13.11.3 AnHorn Medicines Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 AnHorn Medicines Main Business Overview

13.11.5 AnHorn Medicines Latest Developments

13.12 Astellas

13.12.1 Astellas Company Information

13.12.2 Astellas Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.12.3 Astellas Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Astellas Main Business Overview

13.12.5 Astellas Latest Developments

13.13 Auron Therapeutics

13.13.1 Auron Therapeutics Company Information

13.13.2 Auron Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.13.3 Auron Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 Auron Therapeutics Main Business Overview

13.13.5 Auron Therapeutics Latest Developments

13.14 Axter Therapeutics

13.14.1 Axter Therapeutics Company Information

13.14.2 Axter Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.14.3 Axter Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.14.4 Axter Therapeutics Main Business Overview

13.14.5 Axter Therapeutics Latest Developments

13.15 Biotheryx

13.15.1 Biotheryx Company Information

13.15.2 Biotheryx Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.15.3 Biotheryx Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.15.4 Biotheryx Main Business Overview

13.15.5 Biotheryx Latest Developments

13.16 Dialectic Therapeutics

13.16.1 Dialectic Therapeutics Company Information

13.16.2 Dialectic Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.16.3 Dialectic Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.16.4 Dialectic Therapeutics Main Business Overview

13.16.5 Dialectic Therapeutics Latest Developments

13.17 Hinova

13.17.1 Hinova Company Information

13.17.2 Hinova Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.17.3 Hinova Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.17.4 Hinova Main Business Overview

13.17.5 Hinova Latest Developments

13.18 Hinova Pharmaceuticals

13.18.1 Hinova Pharmaceuticals Company Information

13.18.2 Hinova Pharmaceuticals Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.18.3 Hinova Pharmaceuticals Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.18.4 Hinova Pharmaceuticals Main Business Overview

13.18.5 Hinova Pharmaceuticals Latest Developments

13.19 Haisco

13.19.1 Haisco Company Information

13.19.2 Haisco Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.19.3 Haisco Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.19.4 Haisco Main Business Overview

13.19.5 Haisco Latest Developments

13.20 Leadingtac

13.20.1 Leadingtac Company Information

13.20.2 Leadingtac Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.20.3 Leadingtac Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.20.4 Leadingtac Main Business Overview

13.20.5 Leadingtac Latest Developments

13.21 Mitsubishi Tanabe Pharma America

- 13.21.1 Mitsubishi Tanabe Pharma America Company Information
- 13.21.2 Mitsubishi Tanabe Pharma America Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications
- 13.21.3 Mitsubishi Tanabe Pharma America Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.21.4 Mitsubishi Tanabe Pharma America Main Business Overview
- 13.21.5 Mitsubishi Tanabe Pharma America Latest Developments
- 13.22 NiKang Therapeutics
 - 13.22.1 NiKang Therapeutics Company Information
 - 13.22.2 NiKang Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications
 - 13.22.3 NiKang Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.22.4 NiKang Therapeutics Main Business Overview
 - 13.22.5 NiKang Therapeutics Latest Developments
- 13.23 Ubix Therapeutics
 - 13.23.1 Ubix Therapeutics Company Information
 - 13.23.2 Ubix Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications
 - 13.23.3 Ubix Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.23.4 Ubix Therapeutics Main Business Overview
 - 13.23.5 Ubix Therapeutics Latest Developments
- 13.24 Foghorn Therapeutics
 - 13.24.1 Foghorn Therapeutics Company Information
 - 13.24.2 Foghorn Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications
 - 13.24.3 Foghorn Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.24.4 Foghorn Therapeutics Main Business Overview
 - 13.24.5 Foghorn Therapeutics Latest Developments
- 13.25 Beigene, Ltd.
 - 13.25.1 Beigene, Ltd. Company Information
 - 13.25.2 Beigene, Ltd. Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications
 - 13.25.3 Beigene, Ltd. Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.25.4 Beigene, Ltd. Main Business Overview
 - 13.25.5 Beigene, Ltd. Latest Developments

13.26 Jiangsu Hengrui Medicine

13.26.1 Jiangsu Hengrui Medicine Company Information

13.26.2 Jiangsu Hengrui Medicine Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.26.3 Jiangsu Hengrui Medicine Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.26.4 Jiangsu Hengrui Medicine Main Business Overview

13.26.5 Jiangsu Hengrui Medicine Latest Developments

13.27 Qilu Pharmaceutical

13.27.1 Qilu Pharmaceutical Company Information

13.27.2 Qilu Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.27.3 Qilu Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.27.4 Qilu Pharmaceutical Main Business Overview

13.27.5 Qilu Pharmaceutical Latest Developments

13.28 Simcere Pharma

13.28.1 Simcere Pharma Company Information

13.28.2 Simcere Pharma Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.28.3 Simcere Pharma Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.28.4 Simcere Pharma Main Business Overview

13.28.5 Simcere Pharma Latest Developments

13.29 Chia Tai Tianqing Pharmaceutical

13.29.1 Chia Tai Tianqing Pharmaceutical Company Information

13.29.2 Chia Tai Tianqing Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

13.29.3 Chia Tai Tianqing Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.29.4 Chia Tai Tianqing Pharmaceutical Main Business Overview

13.29.5 Chia Tai Tianqing Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Targeted Protein Degradation (TPD) Therapy Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Targeted Protein Degradation (TPD) Therapy Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of PROTAC

Table 4. Major Players of Molecular Glues

Table 5. Major Players of Others

Table 6. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales by Type (2021-2026) & (K Units)

Table 7. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Type (2021-2026)

Table 8. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Type (2021-2026) & (\$ million)

Table 9. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Type (2021-2026)

Table 10. Global Targeted Protein Degradation (TPD) Therapy Drugs Sale Price by Type (2021-2026) & (US\$/Unit)

Table 11. Major Players of Degradation of Transcription Factors Type

Table 12. Major Players of Degradation of Scaffold Proteins Type

Table 13. Major Players of Others

Table 14. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales by Target Protein (2021-2026) & (K Units)

Table 15. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Target Protein (2021-2026)

Table 16. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Target Protein (2021-2026) & (\$ million)

Table 17. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Target Protein (2021-2026)

Table 18. Global Targeted Protein Degradation (TPD) Therapy Drugs Sale Price by Target Protein (2021-2026) & (US\$/Unit)

Table 19. Major Players of Oral Drugs

Table 20. Major Players of Injectable Drugs

Table 21. Major Players of Others

Table 22. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales by Administration Route (2021-2026) & (K Units)

Table 23. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Administration Route (2021-2026)

Table 24. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Administration Route (2021-2026) & (\$ million)

Table 25. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Administration Route (2021-2026)

Table 26. Global Targeted Protein Degradation (TPD) Therapy Drugs Sale Price by Administration Route (2021-2026) & (US\$/Unit)

Table 27. Global Targeted Protein Degradation (TPD) Therapy Drugs Sale by Application (2021-2026) & (K Units)

Table 28. Global Targeted Protein Degradation (TPD) Therapy Drugs Sale Market Share by Application (2021-2026)

Table 29. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Application (2021-2026) & (\$ million)

Table 30. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Application (2021-2026)

Table 31. Global Targeted Protein Degradation (TPD) Therapy Drugs Sale Price by Application (2021-2026) & (US\$/Unit)

Table 32. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales by Company (2021-2026) & (K Units)

Table 33. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Company (2021-2026)

Table 34. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Company (2021-2026) & (\$ millions)

Table 35. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Company (2021-2026)

Table 36. Global Targeted Protein Degradation (TPD) Therapy Drugs Sale Price by Company (2021-2026) & (US\$/Unit)

Table 37. Key Manufacturers Targeted Protein Degradation (TPD) Therapy Drugs Producing Area Distribution and Sales Area

Table 38. Players Targeted Protein Degradation (TPD) Therapy Drugs Products Offered

Table 39. Targeted Protein Degradation (TPD) Therapy Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 40. New Products and Potential Entrants

Table 41. Market M&A Activity & Strategy

Table 42. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales by Geographic Region (2021-2026) & (K Units)

Table 43. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share Geographic Region (2021-2026)

Table 44. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 45. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Geographic Region (2021-2026)

Table 46. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales by Country/Region (2021-2026) & (K Units)

Table 47. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Country/Region (2021-2026)

Table 48. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Country/Region (2021-2026) & (\$ millions)

Table 49. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Country/Region (2021-2026)

Table 50. Americas Targeted Protein Degradation (TPD) Therapy Drugs Sales by Country (2021-2026) & (K Units)

Table 51. Americas Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Country (2021-2026)

Table 52. Americas Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Country (2021-2026) & (\$ millions)

Table 53. Americas Targeted Protein Degradation (TPD) Therapy Drugs Sales by Type (2021-2026) & (K Units)

Table 54. Americas Targeted Protein Degradation (TPD) Therapy Drugs Sales by Application (2021-2026) & (K Units)

Table 55. APAC Targeted Protein Degradation (TPD) Therapy Drugs Sales by Region (2021-2026) & (K Units)

Table 56. APAC Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Region (2021-2026)

Table 57. APAC Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Region (2021-2026) & (\$ millions)

Table 58. APAC Targeted Protein Degradation (TPD) Therapy Drugs Sales by Type (2021-2026) & (K Units)

Table 59. APAC Targeted Protein Degradation (TPD) Therapy Drugs Sales by Application (2021-2026) & (K Units)

Table 60. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales by Country (2021-2026) & (K Units)

Table 61. Europe Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Country (2021-2026) & (\$ millions)

Table 62. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales by Type (2021-2026) & (K Units)

Table 63. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales by

Application (2021-2026) & (K Units)

Table 64. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales by Country (2021-2026) & (K Units)

Table 65. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Country (2021-2026)

Table 66. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales by Type (2021-2026) & (K Units)

Table 67. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales by Application (2021-2026) & (K Units)

Table 68. Key Market Drivers & Growth Opportunities of Targeted Protein Degradation (TPD) Therapy Drugs

Table 69. Key Market Challenges & Risks of Targeted Protein Degradation (TPD) Therapy Drugs

Table 70. Key Industry Trends of Targeted Protein Degradation (TPD) Therapy Drugs

Table 71. Targeted Protein Degradation (TPD) Therapy Drugs Raw Material

Table 72. Key Suppliers of Raw Materials

Table 73. Targeted Protein Degradation (TPD) Therapy Drugs Distributors List

Table 74. Targeted Protein Degradation (TPD) Therapy Drugs Customer List

Table 75. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Forecast by Region (2027-2032) & (K Units)

Table 76. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 77. Americas Targeted Protein Degradation (TPD) Therapy Drugs Sales Forecast by Country (2027-2032) & (K Units)

Table 78. Americas Targeted Protein Degradation (TPD) Therapy Drugs Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 79. APAC Targeted Protein Degradation (TPD) Therapy Drugs Sales Forecast by Region (2027-2032) & (K Units)

Table 80. APAC Targeted Protein Degradation (TPD) Therapy Drugs Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 81. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Forecast by Country (2027-2032) & (K Units)

Table 82. Europe Targeted Protein Degradation (TPD) Therapy Drugs Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 83. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Forecast by Country (2027-2032) & (K Units)

Table 84. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 85. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Forecast by

Type (2027-2032) & (K Units)

Table 86. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 87. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Forecast by Application (2027-2032) & (K Units)

Table 88. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 89. BMS Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 90. BMS Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 91. BMS Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 92. BMS Main Business

Table 93. BMS Latest Developments

Table 94. Arvinas Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 95. Arvinas Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 96. Arvinas Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 97. Arvinas Main Business

Table 98. Arvinas Latest Developments

Table 99. Kymera Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 100. Kymera Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 101. Kymera Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 102. Kymera Main Business

Table 103. Kymera Latest Developments

Table 104. Nurix Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 105. Nurix Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 106. Nurix Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 107. Nurix Main Business

Table 108. Nurix Latest Developments

Table 109. C4 Therapeutics Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 110. C4 Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 111. C4 Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 112. C4 Therapeutics Main Business

Table 113. C4 Therapeutics Latest Developments

Table 114. Cullgen Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 115. Cullgen Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 116. Cullgen Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 117. Cullgen Main Business

Table 118. Cullgen Latest Developments

Table 119. Kintor Pharma Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 120. Kintor Pharma Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 121. Kintor Pharma Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 122. Kintor Pharma Main Business

Table 123. Kintor Pharma Latest Developments

Table 124. Prelude Therapeutics Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 125. Prelude Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 126. Prelude Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 127. Prelude Therapeutics Main Business

Table 128. Prelude Therapeutics Latest Developments

Table 129. AbbVie Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 130. AbbVie Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 131. AbbVie Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 132. AbbVie Main Business

Table 133. AbbVie Latest Developments

Table 134. Accutar Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 135. Accutar Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 136. Accutar Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 137. Accutar Main Business

Table 138. Accutar Latest Developments

Table 139. AnHorn Medicines Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 140. AnHorn Medicines Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 141. AnHorn Medicines Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 142. AnHorn Medicines Main Business

Table 143. AnHorn Medicines Latest Developments

Table 144. Astellas Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 145. Astellas Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 146. Astellas Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 147. Astellas Main Business

Table 148. Astellas Latest Developments

Table 149. Auron Therapeutics Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 150. Auron Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 151. Auron Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 152. Auron Therapeutics Main Business

Table 153. Auron Therapeutics Latest Developments

Table 154. Axter Therapeutics Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 155. Axter Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 156. Axter Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 157. Axter Therapeutics Main Business

Table 158. Axter Therapeutics Latest Developments

Table 159. Biotheryx Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 160. Biotheryx Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 161. Biotheryx Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 162. Biotheryx Main Business

Table 163. Biotheryx Latest Developments

Table 164. Dialectic Therapeutics Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 165. Dialectic Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 166. Dialectic Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 167. Dialectic Therapeutics Main Business

Table 168. Dialectic Therapeutics Latest Developments

Table 169. Hinoa Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 170. Hinoa Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 171. Hinoa Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 172. Hinoa Main Business

Table 173. Hinoa Latest Developments

Table 174. Hinoa Pharmaceuticals Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 175. Hinoa Pharmaceuticals Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 176. Hinoa Pharmaceuticals Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 177. Hinoa Pharmaceuticals Main Business

Table 178. Hinoa Pharmaceuticals Latest Developments

Table 179. Haisco Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 180. Haisco Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 181. Haisco Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 182. Haisco Main Business

Table 183. Haisco Latest Developments

Table 184. Leadingtac Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 185. Leadingtac Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 186. Leadingtac Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 187. Leadingtac Main Business

Table 188. Leadingtac Latest Developments

Table 189. Mitsubishi Tanabe Pharma America Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 190. Mitsubishi Tanabe Pharma America Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 191. Mitsubishi Tanabe Pharma America Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 192. Mitsubishi Tanabe Pharma America Main Business

Table 193. Mitsubishi Tanabe Pharma America Latest Developments

Table 194. NiKang Therapeutics Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 195. NiKang Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 196. NiKang Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 197. NiKang Therapeutics Main Business

Table 198. NiKang Therapeutics Latest Developments

Table 199. Ubix Therapeutics Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 200. Ubix Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 201. Ubix Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 202. Ubix Therapeutics Main Business

Table 203. Ubix Therapeutics Latest Developments

Table 204. Foghorn Therapeutics Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 205. Foghorn Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 206. Foghorn Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 207. Foghorn Therapeutics Main Business

Table 208. Foghorn Therapeutics Latest Developments

Table 209. Beigene, Ltd. Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 210. Beigene, Ltd. Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 211. Beigene, Ltd. Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 212. Beigene, Ltd. Main Business

Table 213. Beigene, Ltd. Latest Developments

Table 214. Jiangsu Hengrui Medicine Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 215. Jiangsu Hengrui Medicine Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 216. Jiangsu Hengrui Medicine Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 217. Jiangsu Hengrui Medicine Main Business

Table 218. Jiangsu Hengrui Medicine Latest Developments

Table 219. Qilu Pharmaceutical Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 220. Qilu Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 221. Qilu Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 222. Qilu Pharmaceutical Main Business

Table 223. Qilu Pharmaceutical Latest Developments

Table 224. Simcere Pharma Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 225. Simcere Pharma Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 226. Simcere Pharma Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 227. Simcere Pharma Main Business

Table 228. Simcere Pharma Latest Developments

Table 229. Chia Tai Tianqing Pharmaceutical Basic Information, Targeted Protein Degradation (TPD) Therapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 230. Chia Tai Tianqing Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Product Portfolios and Specifications

Table 231. Chia Tai Tianqing Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 232. Chia Tai Tianqing Pharmaceutical Main Business

Table 233. Chia Tai Tianqing Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Targeted Protein Degradation (TPD) Therapy Drugs
- Figure 2. Targeted Protein Degradation (TPD) Therapy Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Targeted Protein Degradation (TPD) Therapy Drugs Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Country/Region (2025)
- Figure 10. Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of PROTAC
- Figure 12. Product Picture of Molecular Glues
- Figure 13. Product Picture of Others
- Figure 14. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Type in 2026
- Figure 15. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Type (2021-2026)
- Figure 16. Product Picture of Degradation of Transcription Factors Type
- Figure 17. Product Picture of Degradation of Scaffold Proteins Type
- Figure 18. Product Picture of Others
- Figure 19. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Target Protein in 2026
- Figure 20. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Target Protein (2021-2026)
- Figure 21. Product Picture of Oral Drugs
- Figure 22. Product Picture of Injectable Drugs
- Figure 23. Product Picture of Others
- Figure 24. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Administration Route in 2026
- Figure 25. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market

Share by Administration Route (2021-2026)

Figure 26. Targeted Protein Degradation (TPD) Therapy Drugs Consumed in Cancer

Figure 27. Global Targeted Protein Degradation (TPD) Therapy Drugs Market: Cancer (2021-2026) & (K Units)

Figure 28. Targeted Protein Degradation (TPD) Therapy Drugs Consumed in Immune Diseases

Figure 29. Global Targeted Protein Degradation (TPD) Therapy Drugs Market: Immune Diseases (2021-2026) & (K Units)

Figure 30. Targeted Protein Degradation (TPD) Therapy Drugs Consumed in Others

Figure 31. Global Targeted Protein Degradation (TPD) Therapy Drugs Market: Others (2021-2026) & (K Units)

Figure 32. Global Targeted Protein Degradation (TPD) Therapy Drugs Sale Market Share by Application (2025)

Figure 33. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Application in 2026

Figure 34. Targeted Protein Degradation (TPD) Therapy Drugs Sales by Company in 2026 (K Units)

Figure 35. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Company in 2026

Figure 36. Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Company in 2026 (\$ millions)

Figure 37. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Company in 2026

Figure 38. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Geographic Region (2021-2026)

Figure 39. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Geographic Region in 2026

Figure 40. Americas Targeted Protein Degradation (TPD) Therapy Drugs Sales 2021-2026 (K Units)

Figure 41. Americas Targeted Protein Degradation (TPD) Therapy Drugs Revenue 2021-2026 (\$ millions)

Figure 42. APAC Targeted Protein Degradation (TPD) Therapy Drugs Sales 2021-2026 (K Units)

Figure 43. APAC Targeted Protein Degradation (TPD) Therapy Drugs Revenue 2021-2026 (\$ millions)

Figure 44. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales 2021-2026 (K Units)

Figure 45. Europe Targeted Protein Degradation (TPD) Therapy Drugs Revenue 2021-2026 (\$ millions)

Figure 46. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales 2021-2026 (K Units)

Figure 47. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Revenue 2021-2026 (\$ millions)

Figure 48. Americas Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Country in 2026

Figure 49. Americas Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Country (2021-2026)

Figure 50. Americas Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Type (2021-2026)

Figure 51. Americas Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Application (2021-2026)

Figure 52. United States Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 53. Canada Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 54. Mexico Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 55. Brazil Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 56. APAC Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Region in 2026

Figure 57. APAC Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Region (2021-2026)

Figure 58. APAC Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Type (2021-2026)

Figure 59. APAC Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Application (2021-2026)

Figure 60. China Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 61. Japan Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 62. South Korea Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 63. Southeast Asia Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 64. India Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 65. Australia Targeted Protein Degradation (TPD) Therapy Drugs Revenue

Growth 2021-2026 (\$ millions)

Figure 66. China Taiwan Targeted Protein Degradation (TPD) Therapy Drugs Revenue

Growth 2021-2026 (\$ millions)

Figure 67. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Country in 2026

Figure 68. Europe Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Country (2021-2026)

Figure 69. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Type (2021-2026)

Figure 70. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Application (2021-2026)

Figure 71. Germany Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 72. France Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 73. UK Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 74. Italy Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 75. Russia Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 76. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Country (2021-2026)

Figure 77. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Type (2021-2026)

Figure 78. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Share by Application (2021-2026)

Figure 79. Egypt Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 80. South Africa Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 81. Israel Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 82. Turkey Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 83. GCC Countries Targeted Protein Degradation (TPD) Therapy Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 84. Manufacturing Cost Structure Analysis of Targeted Protein Degradation (TPD) Therapy Drugs in 2026

Figure 85. Manufacturing Process Analysis of Targeted Protein Degradation (TPD) Therapy Drugs

Figure 86. Industry Chain Structure of Targeted Protein Degradation (TPD) Therapy Drugs

Figure 87. Channels of Distribution

Figure 88. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Market Forecast by Region (2027-2032)

Figure 89. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share Forecast by Region (2027-2032)

I would like to order

Product name: Global Targeted Protein Degradation (TPD) Therapy Drugs Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G22EDE2BB372EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G22EDE2BB372EN.html>